[Recombinant human DNase in conditions other than cystic fibrosis].
Recombinant human DNase (rhDNase) reduces viscosity of sputum. Effect has been documented in cystic fibrosis and postoperatively in paediatric heart disease. Single dose treatment with rhDNase in paediatric asthma has no effect. In respiratory syncytial virus infection, treatment with rhDNase may be associated with increased need for supplemental oxygen. In adults with idiopathic bronchiectasis, treatment with rhDNase leads to more pulmonary exacerbations and a greater decline in pulmonary function tests. There are no controlled studies on rhDNase in primary ciliary dyskinesia or atelectasis.
Kristensen
Kim
K
Paediatrisk Klinik 2, 4072, Rigshospitalet, DK-2100 København Ø, Denmark. kimk@dadlnet.dk
D000280:Administration, Inhalation; D000328:Adult; D001249:Asthma / Q000188:drug therapy; D001987:Bronchiectasis / Q000188:drug therapy; D002648:Child; D002925:Ciliary Motility Disorders / Q000188:drug therapy; D000075202:Contraindications; D003850:Deoxyribonuclease I / Q000008:administration & dosage*; D006801:Humans; D007619:Kartagener Syndrome / Q000188:drug therapy; D011183:Postoperative Complications / Q000188:drug therapy; D001261:Pulmonary Atelectasis / Q000188:drug therapy; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy; D012140:Respiratory Tract Diseases / Q000188:drug therapy*; D016896:Treatment Outcome
C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I